Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women

Many investigations have found common occurrences of benign paroxysmal positional vertigo (BPPV) in women, and clinical experience has shown that BPPV can develop due to increased hormonal fluctuations, especially during menopause. Therefore, knowledge about neurochemicals and their involvement with...

Full description

Bibliographic Details
Main Author: Seong-Hae Jeong
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-10-01
Series:Frontiers in Neurology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fneur.2020.589605/full
id doaj-a58b532a187a41b7b79ba974df749172
record_format Article
spelling doaj-a58b532a187a41b7b79ba974df7491722020-11-25T03:41:11ZengFrontiers Media S.A.Frontiers in Neurology1664-22952020-10-011110.3389/fneur.2020.589605589605Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal WomenSeong-Hae JeongMany investigations have found common occurrences of benign paroxysmal positional vertigo (BPPV) in women, and clinical experience has shown that BPPV can develop due to increased hormonal fluctuations, especially during menopause. Therefore, knowledge about neurochemicals and their involvement with BPPV is imperative for the management of neurological issues in women. This review will discuss appropriate gender-based considerations of BPPV based on experimental and clinical evidence. The studies describe 2 lines of evidence regarding the association of perimenopause in women and the development of BPPV: (1) experimental evidence: the existence of estrogen receptors in the inner ear, otoconial malformations in osteopenic/osteoporotic rats, changes in otoconin 90 caused by hormone replacement therapy, and impaired calcium absorption following estrogen deprivation corrected by estrogen replacement therapy and (2) clinical evidence: epidemiological aspects, osteoporosis and estrogen deficiency. Future studies are necessary to validate the effects of hormonal replacement therapy and phytoestrogen in women with recurrent BPPV.https://www.frontiersin.org/article/10.3389/fneur.2020.589605/fullvertigoestrogenwomenotoconiaperimenopause
collection DOAJ
language English
format Article
sources DOAJ
author Seong-Hae Jeong
spellingShingle Seong-Hae Jeong
Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
Frontiers in Neurology
vertigo
estrogen
women
otoconia
perimenopause
author_facet Seong-Hae Jeong
author_sort Seong-Hae Jeong
title Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
title_short Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
title_full Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
title_fullStr Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
title_full_unstemmed Benign Paroxysmal Positional Vertigo Risk Factors Unique to Perimenopausal Women
title_sort benign paroxysmal positional vertigo risk factors unique to perimenopausal women
publisher Frontiers Media S.A.
series Frontiers in Neurology
issn 1664-2295
publishDate 2020-10-01
description Many investigations have found common occurrences of benign paroxysmal positional vertigo (BPPV) in women, and clinical experience has shown that BPPV can develop due to increased hormonal fluctuations, especially during menopause. Therefore, knowledge about neurochemicals and their involvement with BPPV is imperative for the management of neurological issues in women. This review will discuss appropriate gender-based considerations of BPPV based on experimental and clinical evidence. The studies describe 2 lines of evidence regarding the association of perimenopause in women and the development of BPPV: (1) experimental evidence: the existence of estrogen receptors in the inner ear, otoconial malformations in osteopenic/osteoporotic rats, changes in otoconin 90 caused by hormone replacement therapy, and impaired calcium absorption following estrogen deprivation corrected by estrogen replacement therapy and (2) clinical evidence: epidemiological aspects, osteoporosis and estrogen deficiency. Future studies are necessary to validate the effects of hormonal replacement therapy and phytoestrogen in women with recurrent BPPV.
topic vertigo
estrogen
women
otoconia
perimenopause
url https://www.frontiersin.org/article/10.3389/fneur.2020.589605/full
work_keys_str_mv AT seonghaejeong benignparoxysmalpositionalvertigoriskfactorsuniquetoperimenopausalwomen
_version_ 1724531160786141184